📊 BME Key Takeaways
Is BlackRock Health Sciences Trust (BME) a Good Investment?
BlackRock Health Sciences Trust (BME) is a closed-end fund with insufficient fundamental data available for meaningful analysis. With only 1 metric available and no income statement, balance sheet, or cash flow data provided, a comprehensive assessment of financial health and performance is not possible.
BlackRock Health Sciences Trust posted a strong 2025 recovery in net assets and NAV, with net assets rising to about $568.3 million from $546.1 million and NAV per share increasing to $43.97 from $41.20, driven mainly by realized and unrealized investment gains. Financial health is solid because the trust appears effectively unlevered, but growth quality is mixed since distributions materially exceeded net investment income and remained partly dependent on capital gains and return of capital.
Why Buy BlackRock Health Sciences Trust Stock? BME Key Strengths
- Listed on NYSE indicating established market presence
- Recent insider activity (2 Form 4 filings in last 90 days) suggesting management engagement
- BlackRock sponsorship provides institutional backing and professional management
- Net assets and NAV per share increased in 2025, indicating improved portfolio profitability and balance-sheet resilience
- No meaningful debt or leverage burden, which reduces financial risk and interest-rate sensitivity
- Strong realized and unrealized gains in 2025 more than offset distributions and share repurchases
BME Stock Risks: BlackRock Health Sciences Trust Investment Risks
- Severe data quality issues with 99% of fundamental metrics unavailable
- No profitability, liquidity, or solvency metrics to assess financial health
- Inability to evaluate portfolio performance, distributions, or fund stability without financial statements
- Net investment income is low relative to distributions, making payout sustainability dependent on market gains rather than recurring income
- High concentration in healthcare and biotech-related holdings increases sector-specific volatility and regulatory risk
- Part of shareholder distributions has been classified as return of capital, which can erode NAV if portfolio performance weakens
Key Metrics to Watch
- Net Asset Value (NAV) per share and NAV trends
- Distribution yield and payout sustainability
- Portfolio composition and sector exposure within healthcare
- NAV per share and total net assets
- Distribution coverage from net investment income plus realized gains
BlackRock Health Sciences Trust (BME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BME Profit Margin, ROE & Profitability Analysis
BME vs Market Sector: How BlackRock Health Sciences Trust Compares
How BlackRock Health Sciences Trust compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BlackRock Health Sciences Trust Stock Overvalued? BME Valuation Analysis 2026
Based on fundamental analysis, BlackRock Health Sciences Trust has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BlackRock Health Sciences Trust Balance Sheet: BME Debt, Cash & Liquidity
BME Revenue Growth, EPS Growth & YoY Performance
BME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BlackRock Health Sciences Trust (CIK: 0001314966)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BME
What is the AI rating for BME?
BlackRock Health Sciences Trust (BME) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 46% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BME's key strengths?
Claude: Listed on NYSE indicating established market presence. Recent insider activity (2 Form 4 filings in last 90 days) suggesting management engagement. ChatGPT: Net assets and NAV per share increased in 2025, indicating improved portfolio profitability and balance-sheet resilience. No meaningful debt or leverage burden, which reduces financial risk and interest-rate sensitivity.
What are the risks of investing in BME?
Claude: Severe data quality issues with 99% of fundamental metrics unavailable. No profitability, liquidity, or solvency metrics to assess financial health. ChatGPT: Net investment income is low relative to distributions, making payout sustainability dependent on market gains rather than recurring income. High concentration in healthcare and biotech-related holdings increases sector-specific volatility and regulatory risk.
What is BME's revenue and growth?
BlackRock Health Sciences Trust reported revenue of N/A.
Does BME pay dividends?
BlackRock Health Sciences Trust does not currently pay dividends.
Where can I find BME SEC filings?
Official SEC filings for BlackRock Health Sciences Trust (CIK: 0001314966) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BME's EPS?
BlackRock Health Sciences Trust has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BME a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BlackRock Health Sciences Trust has a HOLD rating with 46% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BME stock overvalued or undervalued?
Valuation metrics for BME: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BME stock in 2026?
Our dual AI analysis gives BlackRock Health Sciences Trust a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BME's free cash flow?
BlackRock Health Sciences Trust's operating cash flow is N/A, with capital expenditures of N/A.
How does BME compare to other Market stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 1.8).